drugset
drugset / Trial / NCT03210649

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

NCT03210649 ↗

Phase 1 Completed 18 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519

Timeline

Start
2017-03-07
Primary completion
2017-04-24
Completion
2017-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject ROCACETRAPIB Small molecule 400 mg Oral

Indications

hyperlipidemia